Market open
AbbVie/$ABBV
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Ticker
$ABBV
Sector
Trading on
NYSE
Industry
Biotechnology
Headquarters
Employees
55,000
ISIN
US00287Y1091
Website
AbbVie Metrics
BasicAdvanced
$313B
75.83
$2.34
0.55
$4.74
3.70%
Price and volume
Market cap
$313B
Beta
0.55
52-week high
$218.66
52-week low
$153.58
Average daily volume
9.3M
Dividend rate
$4.74
Financial strength
Current ratio
0.76
Quick ratio
0.485
Long term debt to equity
4,422.845
Total debt to equity
2,021.968
Dividend payout ratio (TTM)
266.46%
Interest coverage (TTM)
6.68%
Management effectiveness
Return on assets (TTM)
8.34%
Return on equity (TTM)
88.40%
Valuation
Price to earnings (TTM)
75.832
Price to revenue (TTM)
5.471
Price to book
220.71
Price to tangible book (TTM)
-3.39
Price to free cash flow (TTM)
20.4
Dividend yield (TTM)
2.67%
Forward dividend yield
3.70%
Growth
Revenue change (TTM)
5.45%
Earnings per share change (TTM)
-30.38%
3-year revenue growth (CAGR)
0.38%
3-year earnings per share growth (CAGR)
-30.53%
3-year dividend per share growth (CAGR)
5.59%
What the Analysts think about AbbVie
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for AbbVie stock.
AbbVie Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AbbVie Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AbbVie News
AllArticlesVideos
Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer
Seeking Alpha·17 hours ago
AbbVie Inc. (ABBV) Presents at BofA Securities 2025 Healthcare Conference (Transcript)
Seeking Alpha·18 hours ago
Calls of the Day: RobinHood, UnitedHealth, Abbvie and Lowe's
CNBC Television·20 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for AbbVie stock?
AbbVie (ABBV) has a market cap of $313B as of May 15, 2025.
What is the P/E ratio for AbbVie stock?
The price to earnings (P/E) ratio for AbbVie (ABBV) stock is 75.83 as of May 15, 2025.
Does AbbVie stock pay dividends?
Yes, the AbbVie (ABBV) stock pays dividends to shareholders. As of May 15, 2025, the dividend rate is $4.74 and the yield is 3.7%. AbbVie has a payout ratio of 266.46% on a trailing twelve-month basis.
When is the next AbbVie dividend payment date?
The next AbbVie (ABBV) dividend payment is scheduled for May 15, 2025.
What is the beta indicator for AbbVie?
AbbVie (ABBV) has a beta rating of 0.55. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.